GlassScriptPhysician profile
James D Perry
NPI 1679893036
$11,889.06
in general payments reported to CMS, 2019-2025
35 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what 77% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $856 · 2021: $1,022 · 2022: $1,300 · 2023: $5,173 · 2024: $1,302 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,754 · Education: $3,238 · Travel and Lodging: $512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,753.51 |
| Education | $3,237.97 |
| Travel and Lodging | $511.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,644.79 | 2023-2024 | Ion, Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $1,289.61 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,056.00 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Regeneron Healthcare Solutions, INC. | $840.54 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $748.05 | 2019-2025 | Ofev, Jascayd |
| Novartis Pharmaceuticals Corporation | $732.44 | 2019-2024 | |
| Genzyme Corporation | $694.35 | 2019-2025 | |
| Insmed, INC. | $359.87 | 2019-2025 | Arikayce, Brinsupri |
| Axsome Therapeutics, INC. | $261.17 | 2022-2025 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $237.97 | 2023-2024 | Opsumit, Uptravi |
| Pulmonx Corporation | $221.39 | 2021-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Jazz Pharmaceuticals INC. | $171.86 | 2019-2022 | |
| Mylan Specialty L.P. | $155.46 | 2019-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $150.66 | 2019-2020 | |
| Genentech USA, INC. | $148.19 | 2019-2024 | Xolair |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $138.97 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $128.58 | 2019-2024 | Capvaxive |
| Amgen INC. | $126.17 | 2023-2025 | Tezspire, Tavneos |
| Grifols USA, LLC | $125.21 | 2023-2025 | Prolastin-C Liquid |
| Electromed, INC. | $98.35 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $90.69 | 2019-2023 | Ultomiris |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $86.52 | 2023 | Lifevest |
| Pfizer INC. | $68.12 | 2019-2024 | |
| United Therapeutics Corporation | $63.62 | 2021-2023 | Tyvaso |
| La Jolla Pharmaceutical Company | $47.10 | 2021-2024 | Giapreza |
| Philips North America LLC | $33.60 | 2019 | |
| Galvanize Therapeutics, INC | $23.03 | 2025 | Aliya System |
| Mallinckrodt Hospital Products INC. | $22.90 | 2023 | Terlivaz |
| Harmony Biosciences LLC | $22.71 | 2024 | |
| Nabriva Therapeutics, Plc | $19.37 | 2020 | |
| Portola Pharmaceuticals, LLC | $18.30 | 2019 | |
| Baxter Healthcare | $17.65 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Ambu INC. | $16.12 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.96 | 2024 | Glassia |
| Advanced Respiratory, INC | $13.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.